Though there are four histone deacetylase (HDAC) inhibitors that are FDA approved to treat some forms of lymphoma, there’s less evidence for their efficacy in solid tumors. Now, new findings in mice ...

Pancreatic cancer is one of the deadliest cancers - only about one in eight patients survives five years after diagnosis. Those dismal statistics are in part due to the thick, nearly impenetrable wall ...

Simultaneous inhibition of phosphoinositide 3-kinase (PI3K) and histone deacetylase (HDAC) is considered a good strategy in cancer treatment, although current PI3K/HDAC dual inhibitors have ...

Most pancreatic tumors are surrounded by a thick, nearly impenetrable wall of fibrosis— scar tissue—that makes it hard for drugs to access and destroy the cancer cells. Researchers at the Salk ...

Researchers from Chongqing Medical University have discovered novel anaplastic lymphoma kinase (ALK) and histone deacetylase (HDAC) dual inhibitors for the treatment of ALK-positive cancer.

Expanding on this foundation of knowledge, researchers in the Zhou Lab and the Cheung Lab at Mount Sinai plan to concentrate on refining class IIa HDAC inhibitors with better efficacies for treating ...

ABT-301, an HDAC1/2/3 inhibitor, enhances immune response and tumor microenvironment, potentially improving immune checkpoint inhibitor efficacy in metastatic colorectal cancer. The phase 1/2 trial ...

Phase 1/2 of EO2463 immunotherapy as monotherapy and in combination with lenalidomide and/or rituximab in indolent NHL (EONHL1-20/SIDNEY). This is an ASCO Meeting Abstract from the 2024 ASCO Annual ...

Epigenetics is the study of changes in organisms caused by modifying gene expression - by alcohol, for example - rather than alteration of the genetic code itself. Recent evidence suggests that ...

It's our newest approach on the block in terms of approval. So I think we're still understanding it as a community because it's relatively recent, but the clinical trial work certainly did show ...